Brief: ARCA Biopharma Reports Topline Results For Aspen-Covid-19 Phase 2B Clinical Trial
31/03/2022 22:16
March 31 (Reuters) - ARCA Biopharma Inc ABIO.O :
* ARCA BIOPHARMA REPORTS TOPLINE RESULTS FOR ASPEN-COVID-19
PHASE
2B CLINICAL TRIAL
* ARCA BIOPHARMA INC - DID NOT ACHIEVE STUDY PRIMARY
ENDPOINT FOR
ASPEN-COVID-19 PHASE 2B CLINICAL TRIAL
* ARCA BIOPHARMA INC - EVALUATING OPTIONS FOR DEVELOPMENT OF
ITS
ASSETS, INCLUDING PARTNERING AND OTHER STRATEGIC OPTIONS
Source text for Eikon: ID:nGNX2V00R
Further company coverage: ABIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oruka Therapeutics
See all newsOruka falls after reporting mid-stage data for psoriasis drug
Brief: Oruka Therapeutics Announces Positive Week 28 Data For Orka-001 From The Ongoing Everlast-A Trial Showing Deepening Of Responses Without Additional Dosing
Brief: Oruka Therapeutics Appoints Todd Edwards As Chief Commercial Officer
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Oruka Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary